Oncology will maintain its leading position in the pharma industry in 2018. The cancer drug market will be worth approximately $100bn in 2017. The 30 main cancer drugs have generated approximately 12% of their respective manufacturers’ revenues over the first 9 months of 2017–a trend expected to remain steady next year.
All the oncology giants–Merck & Co, Bristol-Myers Squibb, Pfizer and Roche–expect a strong increase in their oncology divisions’ revenues in 2018. These results justify the billion-sized investments already announced by the big pharma, aimed at developing pipelines that–according to EY Advisory Services–already include as many as 1,800 molecules potentially efficient in treating cancer.
Large groups will focus on immunotherapy, a novel business which has been the main target of the latest mergers and acquisitions–suffice it to mention Gilead’s purchase of Kite and Roche’s purchase of Ignyta.